Narcotics can safely and effectively ease chronic severe pain in patients aged 60 or over with little risk of their wanting ever increasing doses, a study has found. But it found that patients younger than 50 are likely to want to rapidly increase their doses, risking addiction.
The study, by researchers from the University of California at San Francisco, looked at the medical records of 206 patients who had been treated for two years for severe pain that wasn't related to cancer. It also showed that the older patients gained long term pain relief from opioid treatment, whereas no long term benefit was seen in the younger group.
The study, to be published in the June issue of Anesthesia and Analgesia (2005;100:1740-5), systematically compared the two groups' desire and need for increases in the dosage of opioids such as morphine, methadone, and oxycodone. It indicates that these drugs may be underprescribed among older patients but may pose risks for younger patients.
The patients had either neuropathic pain or arthritis, fibromyalgia, and related conditions (nociceptive pain). The data showed that both age groups started with similar doses of morphine-like drugs and both took about 14 to 15 months to reach their peak dose. But the average peak dose of the younger group—in many cases well over half a gram a day—was more than twice that of the older group.
Dr Pamela Palmer, the senior author and professor of anaesthesia at the university and director of its Pain Management Center, said that long term use of opioids at moderate levels does not pose an increased risk of cardiac or kidney damage or gastric ulcers, as some cyclo-oxygenase-2 inhibitors do—a risk that is of greater concern for older patients than younger ones. Side effects of opioids, such as sedation and constipation, can be managed by selection and dosage of the drug and by appropriate other drugs.
But younger patients, being more vulnerable to opioid tolerance and at much lower risk of heart attack and gastrointestinal bleeding linked to anti-inflammatory drugs, may be better candidates for the newer non-steroidal anti-inflammatory drugs, the study concludes.
The researchers speculate that the difference between younger and older patients may be due to molecular changes in neurones that occur with ageing. They plan a prospective study for the future.
